MedTrace Logo

Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

NCT02783625 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2026-04-24

No results posted yet for this study

Summary

The purpose of this study is to test the safety of a study drug called duvelisib.

Conditions

  • Lymphoma
  • Relapsed/Refractory T-cell Lymphomas

Interventions

DRUG

Romidepsin

DRUG

Bortezomib

DRUG

duvelisib

Sponsors & Collaborators

Principal Investigators

  • Steven Horwitz, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-23
Primary Completion
2026-04-21
Completion
2026-04-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02783625 on ClinicalTrials.gov